Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
December 11, 2023 12:00 ET
|
Disc Medicine Inc
Substantial, dose-dependent reductions in serum hepcidin and increases in serum iron Hematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burdenDISC-0974 was...
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
November 14, 2023 16:44 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 08:30 ET
|
Disc Medicine Inc
Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescentsData from all adult patients in BEACON to be presented in...
Disc Medicine to Participate in Upcoming Investor Conferences
November 08, 2023 16:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
November 02, 2023 09:00 ET
|
Disc Medicine Inc
Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a...
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
October 23, 2023 09:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
October 03, 2023 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
September 20, 2023 16:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine to Participate in Upcoming Investor Conferences
August 30, 2023 16:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023 08:00 ET
|
Disc Medicine Inc
Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end...